Codiak BioSciences. has filed a patent for a method of loading extracellular vesicles with payload molecules using homogenization. The method involves modifying the vesicles with the payload molecule, isolating the modified vesicles, and optionally formulating them into a pharmaceutical composition. GlobalData’s report on Codiak BioSciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Codiak BioSciences, Peptide pharmacophores was a key innovation area identified from patents. Codiak BioSciences's grant share as of September 2023 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Method for loading extracellular vesicles with payload molecules
A recently filed patent (Publication Number: US20230301917A1) describes a method for producing isolated extracellular vesicles that can be used for delivering payload molecules. The method involves modifying the extracellular vesicles by homogenization, which allows for the incorporation of the payload molecule. The modified extracellular vesicles are then isolated and can be optionally formulated into a pharmaceutical composition.
Extracellular vesicles are small membrane-bound structures that are released by cells and play a role in intercellular communication. They have gained significant attention in recent years due to their potential as vehicles for delivering therapeutic molecules to target cells. This patent proposes a method for modifying extracellular vesicles by incorporating a payload molecule, such as a drug or therapeutic agent, through homogenization.
The process involves subjecting the extracellular vesicles to homogenization, which disrupts their membrane and allows for the payload molecule to be incorporated. The modified extracellular vesicles are then isolated, potentially through techniques such as centrifugation or filtration, to separate them from other cellular components. This isolation step ensures that the extracellular vesicles containing the payload molecule are obtained in a pure form.
Furthermore, the patent suggests that the isolated modified extracellular vesicles can be formulated into a pharmaceutical composition. This composition would include a pharmaceutically-acceptable excipient or carrier, which helps to stabilize and deliver the extracellular vesicles to the target cells. The pharmaceutical composition would be in a form suitable for administration to a subject, such as a liquid or solid dosage form.
Overall, this patent presents a method for producing isolated extracellular vesicles that can be used for delivering payload molecules. The incorporation of the payload molecule is achieved through homogenization, and the modified extracellular vesicles are then isolated and potentially formulated into a pharmaceutical composition. This technology has the potential to enhance the delivery of therapeutic molecules and improve targeted drug delivery in various medical applications.
To know more about GlobalData’s detailed insights on Codiak BioSciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
